GENENTECH INC Company Profile

What is the competitive landscape for GENENTECH INC

GENENTECH INC has eight approved drugs.

There are forty-five US patents protecting GENENTECH INC drugs.

There are eight hundred and forty-one patent family members on GENENTECH INC drugs in forty-eight countries and eighty-nine supplementary protection certificates in nineteen countries.

Summary for GENENTECH INC

International Patents:	841
US Patents:	45
Tradenames:	5
Ingredients:	5
NDAs:	8
Drug Master File Entries:	7

Drugs and US Patents for GENENTECH INC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Genentech Inc	XOFLUZA	baloxavir marboxil	TABLET;ORAL	210854-001	Oct 24, 2018		DISCN	Yes	No	11,261,198		Y
Genentech Inc	EVRYSDI	risdiplam	FOR SOLUTION;ORAL	213535-001	Aug 7, 2020		RX	Yes	Yes
Genentech Inc	ITOVEBI	inavolisib	TABLET;ORAL	219249-002	Oct 10, 2024		RX	Yes	Yes	8,343,955
Genentech Inc	ITOVEBI	inavolisib	TABLET;ORAL	219249-002	Oct 10, 2024		RX	Yes	Yes	8,242,104		Y	Y
Genentech Inc	XOFLUZA	baloxavir marboxil	TABLET;ORAL	210854-001	Oct 24, 2018		DISCN	Yes	No	11,306,106
Genentech Inc	ROZLYTREK	entrectinib	CAPSULE;ORAL	212725-001	Aug 15, 2019		RX	Yes	No	9,255,087
Genentech Inc	XOFLUZA	baloxavir marboxil	TABLET;ORAL	210854-003	Mar 18, 2021		RX	Yes	Yes	10,633,397

International Patents for GENENTECH INC Drugs

Country	Patent Number	Estimated Expiration
South Korea	20220165811
South Africa	201707111
Denmark	3428170
South Korea	102705600
Lithuania	3317264
Taiwan	201336842
China	105037259

Supplementary Protection Certificates for GENENTECH INC Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1934174	SPC/GB16/023	United Kingdom		PRODUCT NAME: COBIMETINIB, INCLUDING A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, IN PARTICULAR COBIMETINIB HEMIFUMARATE; REGISTERED: UK EU/1/15/1048/001(NI) 20151124; UK PLGB 00031/0849 20151124
1934174	CA 2016 00021	Denmark		PRODUCT NAME: COBIMETINIB, EVENTUELT I EN HVILKEN SOM HELST FORM BESKYTTET AF GRUNDPATENTET, DER INDBEFATTER FARMACEUTISK ACCEPTABLE SALTE OG SOLVATER, SAERLIGT COBIMETINIB HEMIFUMARAT; REG. NO/DATE: EU/1/15/1048 20151124
1934174	2016C/029	Belgium		PRODUCT NAME: COBIMETINIB IN IEDERE VORM ZOALS BESCHERMD DOOR HET BASISOCTROOI, INCLUSIEF FARMACEUTISCH AANVAARDBARE ZOUTEN EN SOLVATEN DAARVAN, IN HET BIJZONDER COBIMETINIB HEMIFUMARAAT; AUTHORISATION NUMBER AND DATE: EU/1/15/1048 20111120
3143025	2021C/537	Belgium		PRODUCT NAME: RISDIPLAM OF FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/21/1531 20210329
3317284	122025000046	Germany		PRODUCT NAME: INAVOLISIB IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/25/1942 20250718
3317284	CA 2025 00034	Denmark		PRODUCT NAME: INAVOLISIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/25/1942 20250722
2176231	2090052-8	Sweden		PRODUCT NAME: ENTRECTINIB OR TAUTOMERS, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1/20/1460 20200803

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Genentech
• Genentech Inc
• Genera Pharms
• Geneyork Pharms

Pharmaceutical Competitive Landscape Analysis: GENENTECH INC – Market Position, Strengths & Strategic Insights

Last updated: March 25, 2026

What is Genentech’s current market position in the pharmaceutical industry?

Genentech operates as a leading biotechnology firm, primarily focusing on oncology, immunology, neuroscience, and rare diseases. It is a subsidiary of Roche and holds a significant share in oncology and immunology segments.

• Estimated 2022 revenue: $27.6 billion, representing approximately 7% of Roche’s total sales.
• Top products include Herceptin (trastuzumab), Avastin (bevacizumab), Rituxan (rituximab), and Actemra (tocilizumab).
• In the U.S., Genentech ranks among the top biotech firms by sales, with a market share exceeding 15% in oncology (EvaluatePharma, 2022).

How does Genentech compare with key competitors?

Company	Key Focus Areas	2022 Revenue (USD billion)	Major Products	Market Share (Oncology, US)
Amgen	Oncology, hematology, nephrology	25.7	Neulasta, Neupogen, Lumakras	~10%
Novartis	Oncology, hematology, biosimilars	51.9	Gleevec, Kisqali, Cosentyx	~12%
Bristol-Myers Squibb	Oncology, immunology	46.4	Opdivo, Eliquis, Orencia	~18%
Pfizer	Oncology, rare diseases, vaccines	100.3	Ibrance, Xtandi, Prevnar	~12%

Genentech’s stronghold lies in targeted therapies and biologics for cancer and immune disorders. Its focus on novel biologic treatments lends a competitive edge in highly complex treatment areas.

What are Genentech’s core strengths?

• Product Portfolio: A diversified portfolio with multiple blockbusters, including HER2-targeted therapies like Herceptin and immunotherapies like Tecentriq (atezolizumab).
• R&D Capabilities: Robust investment in research, with approximately 20% of sales allocated annually to R&D. It maintains a pipeline of 90+ candidates, emphasizing antibody engineering, cell therapy, and gene editing.
• Regulatory Performance: Consistent success in regulatory approvals, with 12 new biologic approvals over the last five years, well above industry average.
• Partnerships and Collaborations: Strategic alliances with biotech firms and academic institutions bolster innovation and technological access.

What strategic initiatives does Genentech pursue for growth?

• Product Lifecycle Management: Expanding indications through clinical trials, while pursuing biosimilar development for established biologics to maintain revenue streams.
• Pipeline Expansion: Focus on immuno-oncology, antibody-drug conjugates (ADCs), and cell therapies. Current pipeline includes over 40 molecules in late-stage development.
• Digital Transformation: Invests in data analytics, cloud computing, and artificial intelligence to optimize drug discovery and monitor post-market safety.
• Geographic Expansion: Increases presence in emerging markets, especially in Asia-Pacific, to diversify revenue sources.

How does intellectual property (IP) impact Genentech’s competitive leverage?

• Maintains a robust patent portfolio, with over 220 patents granted in 2022, covering biologic manufacturing processes, therapeutic targets, and formulation techniques.
• Strategic patent filings delay biosimilar entry, protecting revenue for vital biologics like Avastin and Herceptin, which face biosimilar competition in the US and Europe.
• Patent expirations scheduled for the next five years could threaten revenues but are offset by pipeline maturity and new product launches.

What are regulatory and market risks influencing Genentech?

• Patent cliffs: Loss of patent exclusivity risks the decline of key products, notably Herceptin and Avastin, in the late 2020s.
• Pricing pressures: Increasing scrutiny from policymakers to reduce biologic prices could impact margins, especially in US markets.
• Regulatory delays: Biosimilar approvals or safety concerns can limit market access or lead to product restrictions.
• Competitive innovation: Rapid advancements by rivals in CAR-T cell therapy and bispecific antibodies could erode Genentech’s market share if it does not keep pace.

How does Genentech’s innovation drive remain competitive?

• Directing over 20% of R&D funds toward emerging modalities such as gene therapy and cell-based immunotherapies.
• Collaborating with biotech startups and academic centers to access pioneering technologies.
• Managing a broad, layered pipeline designed to replace revenue streams from upcoming patent expiries.

Conclusion

Genentech maintains robust market positioning through a diversified biologic portfolio, high R&D investment, and strategic partnerships. While patent expiries and pricing pressures pose risks, its focus on pipeline expansion and technological innovation underpin its ability to sustain growth.

---

Key Takeaways

• Genentech holds a leading position in oncology, with over 15% US market share.
• Its product pipeline emphasizes immuno-oncology, ADCs, and gene therapies.
• The firm’s leadership in biologic innovation is underpinned by extensive patent protections and strategic collaborations.
• Patent expiries and pricing debates require targeted mitigation strategies.
• Continued investment in digital health and emerging modalities will determine long-term competitiveness.

FAQs

1. What are Genentech’s most profitable products?
   Herceptin, Avastin, Rituxan, and Actemra generate the largest revenues, with Herceptin alone contributing over $6 billion annually.

2. How is Genentech defending against biosimilar competition?
   Through patent filings, expanding indications, developing next-generation biologics, and patent litigation strategies.

3. What pipeline therapies are most promising?
   CAR-T therapies, ADCs, and T-cell engagers are in late-stage development, targeting solid tumors, hematologic malignancies, and autoimmune diseases.

4. What markets are strategic for Genentech’s expansion?
   Asia-Pacific and Latin American markets display high growth potential due to increasing healthcare access and unmet medical needs.

5. How does Genentech plan to offset patent expirations?
   By advancing pipeline products, pursuing indications in new therapeutic areas, and leveraging biosimilar opportunities for older biologics.

---

References

1. EvaluatePharma. (2022). World Preview 2022 Data Report.
2. U.S. Food & Drug Administration. (2022). Biologics Approvals.
3. Roche. (2022). Annual Report 2022.